1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Connecticut >
  6. AstraZeneca Acquires Alexion Pharmaceuticals

M&A Deal Summary

AstraZeneca Acquires Alexion Pharmaceuticals

On December 12, 2020, AstraZeneca acquired life science company Alexion Pharmaceuticals for 39.0B USD

Acquisition Highlights
  • This is AstraZeneca’s 12th transaction in the Life Science sector.
  • This is AstraZeneca’s largest (disclosed) transaction.
  • This is AstraZeneca’s 8th transaction in the United States.
  • This is AstraZeneca’s 1st transaction in Connecticut.

M&A Deal Summary
Date 2020-12-12
Target Alexion Pharmaceuticals
Sector Life Science
Buyer(s) AstraZeneca
Deal Type Add-on Acquisition
Deal Value 39.0B USD
Advisor(s) BofA Securities (Financial)
Wachtell, Lipton, Rosen & Katz (Legal)

Target

Alexion Pharmaceuticals

Boston, Connecticut, United States
Alexion Pharmaceuticals is a biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Alexion Pharmaceuticals was formed in 1992 and is based in New Haven, Connecticut.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

AstraZeneca

Cambridge, United Kingdom
Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 54.1B USD (2024)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 14 of 23
Sector: Life Science M&A 12 of 21
Type: Add-on Acquisition M&A Deals 10 of 17
State: Connecticut M&A 1 of 1
Country: United States M&A 8 of 11
Year: 2020 M&A 2 of 2
Size (of disclosed) 1 of 19
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-17 Dogma s Oral PCSK9 Inhibitor Program

Boxford, Massachusetts, United States

Dogma's Oral PCSK9 Inhibitor Program is a protein that regulates the level of low-density lipoprotein (LDL) or ‘bad’ cholesterol in the blood. Increased activity of PCSK9 is associated with high LDL cholesterol.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-11-29 Neogene Therapeutics

Santa Monica, California, United States

Neogene Therapeutics is a global biotechnology company focused on discovering, developing and manufacturing next-generation, transformative TCR therapies targeting neoantigens in solid cancers. Neogene Therapeutics is based in Santa Monica, California.

Buy $320M
Mergr

Solution for

Product

Company

Legal